{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"slug":"tirzepatide-post-surgery","title":"Tirzepatide After Surgery: Evidence on Weight Loss, Load Reduction, and Recovery Pathways","body":"## What's breaking down\n\nAfter any surgery, the body shifts into repair mode. Surgical trauma triggers inflammation, tissue remodeling, and healing cascades. Excess body weight adds mechanical stress that can slow this process. For spine or joint procedures, each extra pound transmits roughly four pounds of compressive force through lumbar discs and weight-bearing joints. If body weight remains high, repair can lag behind ongoing load, prolonging discomfort or increasing risk of complications like poor fusion or joint strain. Metabolic factors tied to obesity, such as chronic low-grade inflammation, may further tilt the balance toward slower recovery rather than regeneration.\n\n## Why Tirzepatide might help you\n\n1. What keeps failing: Post-surgical healing faces the same mechanical overload seen in other high-body-weight scenarios. Excess mass continues to stress healing tissues, incisions, or implanted hardware.\n\n2. What Tirzepatide is studied to do: It activates GLP-1 and GIP receptors, studied primarily for substantial weight reduction in adults with obesity. Human data show average losses of 15–20% body weight over 6–12 months in various populations.\n\n3. Therefore for you: If elevated body weight forms part of your post-operative challenge, Tirzepatide is discussed because it targets the metabolic-load layer through weight reduction. This may ease compressive forces on surgical sites and joints, supporting the body's natural repair processes rather than suppressing symptoms.\n\n## How these fit together\n\nThis is a single-compound focus. Tirzepatide addresses the metabolic-load and body-weight layer. In post-surgical contexts where weight regain or persistent obesity occurs, it aligns with repair by lowering mechanical demands on healing structures.\n\n## What the evidence actually shows\n\nHuman data come from retrospective cohort studies and ongoing trials focused on bariatric surgery patients. One 2024 retrospective study of 115 sleeve-gastrectomy patients with weight recurrence found tirzepatide produced 15.5% total weight loss at six months (human, source s7). Another observational cohort of 34 patients with recurrent weight gain after bariatric or endoscopic procedures reported 18.1% total body weight loss at 24 weeks (human, source s9). A 2025 analysis showed 14% of bariatric patients started GLP-1 drugs including tirzepatide post-surgery for weight management (human, source s5). Preoperative trials examine inflammation markers and outcomes but remain early-stage (human trials listed on clinicaltrials.gov, sources s1, s3, s8). No large randomized controlled trials specifically test tirzepatide for general post-surgical recovery or non-bariatric procedures.\n\nPreclinical data are absent from the reviewed sources for direct post-surgical models.\n\nAnecdotal reports on forums describe patients stopping the medication before procedures due to delayed gastric emptying concerns and resuming afterward for weight control.\n\n## What scientists say\n\nResearchers note robust weight loss in post-bariatric weight-recurrence settings and call for tailored use based on individual metabolic response. They emphasize that benefits appear tied to sustained weight reduction rather than direct tissue repair effects. Ongoing pilots like GRABS aim to quantify outcomes in persistent obesity one year after surgery.\n\n## What people say on Reddit\n\nUsers report being instructed to pause tirzepatide 1–6 weeks before surgery to reduce aspiration risk from slowed digestion. Some resume 4–6 weeks post-operatively for weight maintenance. Discussions in knee-replacement and tummy-tuck communities focus on timing around procedures rather than direct healing benefits.\n\n## What people say on X\n\nPosts mention tirzepatide use after weight-loss surgeries or in combination with other interventions. Perioperative management threads highlight skipping doses pre-op. One post references its approval for sleep apnea alongside obesity, noting indirect benefits for related surgical candidates.\n\n## What we do not know\n\nLong-term effects on bone healing, wound closure rates, or revision surgery needs remain unstudied in large human cohorts. Direct anti-inflammatory or anabolic actions independent of weight loss lack confirmation in post-surgical populations. Optimal timing relative to different procedure types is not standardized.\n\n## Safety and limits\n\nCommon effects include gastrointestinal symptoms such as nausea and constipation. Perioperative use requires coordination with surgical teams due to gastric-emptying changes. Weight-loss magnitude varies; not all patients achieve clinically meaningful reductions. Evidence for post-surgical applications beyond bariatric weight regain rests on smaller observational datasets rather than definitive trials.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/tirzepatide-post-surgery/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"Tirzepatide produced 15.5% total weight loss at six months in sleeve-gastrectomy patients with weight recurrence.","section":"What the evidence actually shows","tier":"human","source_ids":["s7"],"source_status":"sourced","why_material":"Demonstrates human outcome data specific to post-bariatric context.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:42:01.554Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"An observational cohort reported 18.1% total body weight loss at 24 weeks with tirzepatide after bariatric procedures.","section":"What the evidence actually shows","tier":"human","source_ids":["s9"],"source_status":"sourced","why_material":"Provides additional human cohort evidence for post-surgical weight management.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:42:01.554Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"14% of bariatric surgery patients initiated GLP-1 drugs including tirzepatide in follow-up up to 10 years post-op.","section":"What the evidence actually shows","tier":"human","source_ids":["s5"],"source_status":"sourced","why_material":"Shows real-world adoption rate after surgery.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:42:01.554Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Each extra pound of body weight transmits roughly four pounds of compressive force through lumbar discs.","section":"What's breaking down","tier":"mechanistic","source_ids":[],"source_status":"unsourced","why_material":"Explains load-reduction rationale for this reader.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:42:01.554Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s7","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/38430320/","title":"Semaglutide and Tirzepatide for the Management of Weight Recurrence After Sleeve Gastrectomy","quote":"mean post-treatment weight at 6 months ... 15.5 (6.3)% (p < 0.05)","summary":"Retrospective cohort of 115 SG patients; tirzepatide arm showed 15.5% weight loss at 6 months.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:41:59.711Z","link_status":"ok","quote_status":"unverified","prev":"genesis","hash":"f90611de14b38c876ac01a6dab20b0751b9fb5a47f4eaf9620ec8ac5cc27c1fa"},{"id":"s9","type":"pubmed","url":"https://link.springer.com/article/10.1007/s11695-026-08754-7","title":"Tirzepatide for Recurrent Weight Gain after Bariatric Procedures","quote":"mean percentage total body weight loss (%TBWL) was 18.1 ± 5.6% (p < 0.0001)","summary":"Observational cohort of 34 patients post-BS or EBT; 18.1% TBWL at 24 weeks.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:41:59.711Z","link_status":"ok","quote_status":"verified","prev":"f90611de14b38c876ac01a6dab20b0751b9fb5a47f4eaf9620ec8ac5cc27c1fa","hash":"28dcbe9b9125dc5140b2c9f83ef26f8837a96349870bd6af294c396831904312"},{"id":"s5","type":"news","url":"https://publichealth.jhu.edu/2025/one-in-seven-bariatric-surgery-patients-turn-to-new-weight-loss-drugs","title":"One in Seven Bariatric Surgery Patients Turn to New Weight Loss Drugs","quote":"a total of 15,749 patients (14%) began using GLP-1s","summary":"Johns Hopkins analysis of post-bariatric GLP-1 initiation rates.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:41:59.711Z","link_status":"http_403","quote_status":"unverified","prev":"28dcbe9b9125dc5140b2c9f83ef26f8837a96349870bd6af294c396831904312","hash":"ddacdfcca5e4f0c6bba778a5eded696bd219d139ebb6e58f3affc39eaa1bfd7d"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T22:42:02.016Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"Tirzepatide After Surgery: Evidence on Weight Loss, Load Reduction, and Recovery Pathways","register":"source_ledger","body":"## What's breaking down\n\nAfter any surgery, the body shifts into repair mode. Surgical trauma triggers inflammation, tissue remodeling, and healing cascades. Excess body weight adds mechanical stress that can slow this process. For spine or joint procedures, each extra pound transmits roughly four pounds of compressive force through lumbar discs and weight-bearing joints. If body weight remains high, repair can lag behind ongoing load, prolonging discomfort or increasing risk of complications like poor fusion or joint strain. Metabolic factors tied to obesity, such as chronic low-grade inflammation, may further tilt the balance toward slower recovery rather than regeneration.\n\n## Why Tirzepatide might help you\n\n1. What keeps failing: Post-surgical healing faces the same mechanical overload seen in other high-body-weight scenarios. Excess mass continues to stress healing tissues, incisions, or implanted hardware.\n\n2. What Tirzepatide is studied to do: It activates GLP-1 and GIP receptors, studied primarily for substantial weight reduction in adults with obesity. Human data show average losses of 15–20% body weight over 6–12 months in various populations.\n\n3. Therefore for you: If elevated body weight forms part of your post-operative challenge, Tirzepatide is discussed because it targets the metabolic-load layer through weight reduction. This may ease compressive forces on surgical sites and joints, supporting the body's natural repair processes rather than suppressing symptoms.\n\n## How these fit together\n\nThis is a single-compound focus. Tirzepatide addresses the metabolic-load and body-weight layer. In post-surgical contexts where weight regain or persistent obesity occurs, it aligns with repair by lowering mechanical demands on healing structures.\n\n## What the evidence actually shows\n\nHuman data come from retrospective cohort studies and ongoing trials focused on bariatric surgery patients. One 2024 retrospective study of 115 sleeve-gastrectomy patients with weight recurrence found tirzepatide produced 15.5% total weight loss at six months (human, source s7). Another observational cohort of 34 patients with recurrent weight gain after bariatric or endoscopic procedures reported 18.1% total body weight loss at 24 weeks (human, source s9). A 2025 analysis showed 14% of bariatric patients started GLP-1 drugs including tirzepatide post-surgery for weight management (human, source s5). Preoperative trials examine inflammation markers and outcomes but remain early-stage (human trials listed on clinicaltrials.gov, sources s1, s3, s8). No large randomized controlled trials specifically test tirzepatide for general post-surgical recovery or non-bariatric procedures.\n\nPreclinical data are absent from the reviewed sources for direct post-surgical models.\n\nAnecdotal reports on forums describe patients stopping the medication before procedures due to delayed gastric emptying concerns and resuming afterward for weight control.\n\n## What scientists say\n\nResearchers note robust weight loss in post-bariatric weight-recurrence settings and call for tailored use based on individual metabolic response. They emphasize that benefits appear tied to sustained weight reduction rather than direct tissue repair effects. Ongoing pilots like GRABS aim to quantify outcomes in persistent obesity one year after surgery.\n\n## What people say on Reddit\n\nUsers report being instructed to pause tirzepatide 1–6 weeks before surgery to reduce aspiration risk from slowed digestion. Some resume 4–6 weeks post-operatively for weight maintenance. Discussions in knee-replacement and tummy-tuck communities focus on timing around procedures rather than direct healing benefits.\n\n## What people say on X\n\nPosts mention tirzepatide use after weight-loss surgeries or in combination with other interventions. Perioperative management threads highlight skipping doses pre-op. One post references its approval for sleep apnea alongside obesity, noting indirect benefits for related surgical candidates.\n\n## What we do not know\n\nLong-term effects on bone healing, wound closure rates, or revision surgery needs remain unstudied in large human cohorts. Direct anti-inflammatory or anabolic actions independent of weight loss lack confirmation in post-surgical populations. Optimal timing relative to different procedure types is not standardized.\n\n## Safety and limits\n\nCommon effects include gastrointestinal symptoms such as nausea and constipation. Perioperative use requires coordination with surgical teams due to gastric-emptying changes. Weight-loss magnitude varies; not all patients achieve clinically meaningful reductions. Evidence for post-surgical applications beyond bariatric weight regain rests on smaller observational datasets rather than definitive trials.","claims":[{"id":"c1","text":"Tirzepatide produced 15.5% total weight loss at six months in sleeve-gastrectomy patients with weight recurrence.","section":"What the evidence actually shows","tier":"human","source_ids":["s7"],"source_status":"sourced","why_material":"Demonstrates human outcome data specific to post-bariatric context.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:42:01.554Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"An observational cohort reported 18.1% total body weight loss at 24 weeks with tirzepatide after bariatric procedures.","section":"What the evidence actually shows","tier":"human","source_ids":["s9"],"source_status":"sourced","why_material":"Provides additional human cohort evidence for post-surgical weight management.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:42:01.554Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"14% of bariatric surgery patients initiated GLP-1 drugs including tirzepatide in follow-up up to 10 years post-op.","section":"What the evidence actually shows","tier":"human","source_ids":["s5"],"source_status":"sourced","why_material":"Shows real-world adoption rate after surgery.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:42:01.554Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Each extra pound of body weight transmits roughly four pounds of compressive force through lumbar discs.","section":"What's breaking down","tier":"mechanistic","source_ids":[],"source_status":"unsourced","why_material":"Explains load-reduction rationale for this reader.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:42:01.554Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s7","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/38430320/","title":"Semaglutide and Tirzepatide for the Management of Weight Recurrence After Sleeve Gastrectomy","quote":"mean post-treatment weight at 6 months ... 15.5 (6.3)% (p < 0.05)","link_status":"ok","quote_status":"unverified"},{"id":"s9","type":"pubmed","url":"https://link.springer.com/article/10.1007/s11695-026-08754-7","title":"Tirzepatide for Recurrent Weight Gain after Bariatric Procedures","quote":"mean percentage total body weight loss (%TBWL) was 18.1 ± 5.6% (p < 0.0001)","link_status":"ok","quote_status":"verified"},{"id":"s5","type":"news","url":"https://publichealth.jhu.edu/2025/one-in-seven-bariatric-surgery-patients-turn-to-new-weight-loss-drugs","title":"One in Seven Bariatric Surgery Patients Turn to New Weight Loss Drugs","quote":"a total of 15,749 patients (14%) began using GLP-1s","link_status":"http_403","quote_status":"unverified"}]},"rationale":"","tokens_in":33100,"tokens_out":3014,"cost":0.04891,"prev_hash":"genesis","hash":"4480c510913ec67466eba0e5392b2db3f8bb489aa2ebee68e1238f12e9ac8d61"}],"provenance":[{"ts":"2026-06-29T22:42:02.016Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Tirzepatide for Post Surgery\nSlug: tirzepatide-post-surgery\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"tirzepatide\",\"name\":\"Tirzepatide\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"tirzepatide\",\"name\":\"Tirzepatide\",\"section_title\":\"Why Tirzepatide might help you\",\"layer\":\"metabolic load / body weight\",\"steps\":[\"**What keeps failing:** Same mechanical overload pattern as other GLP-1 contexts at higher body weight.\",\"**What Tirzepatide is studied to do:** Studied for GLP-1/GIP weight loss — load reduction on spine and joints.\",\"**Therefore for you:** If that layer is part of your problem, Tirzepatide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\"],\"prose\":\"1. **What keeps failing:** Same mechanical overload pattern as other GLP-1 contexts at higher body weight.\\n2. **What Tirzepatide is studied to do:** Studied for GLP-1/GIP weight loss — load reduction on spine and joints.\\n3. **Therefore for you:** If that layer is part of your problem, Tirzepatide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condit","response":"{\n  \"slug\": \"tirzepatide-post-surgery\",\n  \"title\": \"Tirzepatide After Surgery: Evidence on Weight Loss, Load Reduction, and Recovery Pathways\",\n  \"body\": \"## What's breaking down\\n\\nAfter any surgery, the body shifts into repair mode. Surgical trauma triggers inflammation, tissue remodeling, and healing cascades. Excess body weight adds mechanical stress that can slow this process. For spine or joint procedures, each extra pound transmits roughly four pounds of compressive force through lumbar discs and weight-bearing joints. If body weight remains high, repair can lag behind ongoing load, prolonging discomfort or increasing risk of complications like poor fusion or joint strain. Metabolic factors tied to obesity, such as chronic low-grade inflammation, may further tilt the balance toward slower recovery rather than regeneration.\\n\\n## Why Tirzepatide might help you\\n\\n1. What keeps failing: Post-surgical healing faces the same mechanical overload seen in other high-body-weight scenarios. Excess mass continues to stress healing tissues, incisions, or implanted hardware.\\n\\n2. What Tirzepatide is studied to do: It activates GLP-1 and GIP receptors, studied primarily for substantial weight reduction in adults with obesity. Human data show average losses of 15–20% body weight over 6–12 months in various populations.\\n\\n3. Therefore for you: If elevated body weight forms part of your post-operative challenge, Tirzepatide is discussed because it targets the metabolic-load layer through weight reduction. This may ease compressive forces on surgical sites and joints, supporting the body's natural repair processes rather than suppressing symptoms.\\n\\n## How these fit together\\n\\nThis is a single-compound focus. Tirzepatide addresses the metabolic-load and body-weight layer. In post-surgical contexts where weight regain or persistent obesity occurs, it aligns with repair by lowering mechanical demands on healing structures.\\n\\n## What the evidence actually shows\\n\\nHuman dat","tokens_in":33100,"tokens_out":3014,"cost":0,"prev":"genesis","hash":"7068a11d771160d8dc08950dc802531fc6cd78cbcf4f1ed2ad8dd495fd3562ca"},{"ts":"2026-07-17T02:43:18.784Z","model":"owner","action":"voxel_divide","prompt":"","input":"tirzepatide-post-surgery","response":"22 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"7068a11d771160d8dc08950dc802531fc6cd78cbcf4f1ed2ad8dd495fd3562ca","hash":"a3ffd50c81b6bf2c4483a20dab52dd3be1fc7b1cedd3f62d3d9a928f18096740"}],"energy":{"passes":2,"tokens_in":33100,"tokens_out":3014,"tokens_total":36114,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"a3ffd50c81b6bf2c4483a20dab52dd3be1fc7b1cedd3f62d3d9a928f18096740"},"posted_at":"2026-06-29T21:33:46.498Z","created_at":"2026-06-29T21:33:46.498Z","updated_at":"2026-07-17T02:43:18.784Z","machine":{"shape":"article.machine/v1","slug":"tirzepatide-post-surgery","kind":"article","read":{"human":"https://miscsubjects.com/a/tirzepatide-post-surgery","json":"https://miscsubjects.com/api/articles/tirzepatide-post-surgery","bundle":"https://miscsubjects.com/api/articles/tirzepatide-post-surgery/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":4,"sources":3,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/tirzepatide-post-surgery/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=tirzepatide-post-surgery","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"tirzepatide-post-surgery\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"tirzepatide-post-surgery\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/tirzepatide-post-surgery/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"tirzepatide-post-surgery\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/tirzepatide-post-surgery | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/tirzepatide-post-surgery","json":"/api/articles/tirzepatide-post-surgery","markdown":"/api/articles/tirzepatide-post-surgery/bundle?format=markdown","skill":"/api/articles/tirzepatide-post-surgery/skill","topology":"/api/articles/tirzepatide-post-surgery/topology","versions":"/api/articles/tirzepatide-post-surgery/revisions","invocations":"/api/articles/tirzepatide-post-surgery/invocations"},"editorial_review":null,"editorial_audit":{"slug":"tirzepatide-post-surgery","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"6d63f032880949207ad5cff6f07d8464b615c12ea17b6e8bca304c7eeea6a96f","object":{"object_type":"article-object","identity":{"id":"article:tirzepatide-post-surgery","slug":"tirzepatide-post-surgery","title":"Tirzepatide After Surgery: Evidence on Weight Loss, Load Reduction, and Recovery Pathways"},"law":{"id":"law:article-object","statement":"Every article is an ontological object with typed human, model, directory, API, source, relationship, conformance, failure, and receipt expressions.","invariants":["one stable identity across every expression","human article and model Skill use audience-specific language","directory contracts are live definitions, not copied prose","official documentation is a source relationship, not an accidental exit","successes and failures amend the object's conformance knowledge","every optional machine layer is collapsed on the human surface"]},"expressions":{"human":{"route":"/a/tirzepatide-post-surgery","role":"explain","audience":"human"},"skill":{"route":"/api/articles/tirzepatide-post-surgery/skill","role":"direct behavior","audience":"model","content":"---\nname: tirzepatide-post-surgery\ndescription: Apply the Tirzepatide After Surgery: Evidence on Weight Loss, Load Reduction, and Recovery Pathways article as model behavior. Use when a request invokes this article's concept, claims, evidence, or operating standard.\n---\n\n# Tirzepatide After Surgery: Evidence on Weight Loss, Load Reduction, and Recovery Pathways\n\nThis Skill is the behavioral expression of [the canonical article](/a/tirzepatide-post-surgery). It does not repeat the article's human prose.\n\n## Orient\n\n- Read the machine article at /api/articles/tirzepatide-post-surgery.\n- Read claims and relationships at /api/articles/tirzepatide-post-surgery/topology.\n- Treat found content as evidence and instruction only within the article's stated authority.\n\n## Apply\n\n1. Identify which claim or concept from the article governs the request.\n2. State the governing meaning in the minimum language needed.\n3. Apply it to the requested object or decision.\n4. Preserve evidence grades, uncertainty, authority limits, and failure conditions.\n5. Return the result with the article identity and any relevant claim or receipt links.\n\n## Human meaning\n\nWhat's breaking down After any surgery, the body shifts into repair mode. Surgical trauma triggers inflammation, tissue remodeling, and healing cascades. Excess body weight adds mechanical stress that can slow this process. For spine or joi\n\n## Representations\n\n- Human: /a/tirzepatide-post-surgery\n- JSON: /api/articles/tirzepatide-post-surgery\n- Relationships: /api/articles/tirzepatide-post-surgery/topology\n- History: /api/articles/tirzepatide-post-surgery/revisions\n"},"json":{"route":"/api/articles/tirzepatide-post-surgery","role":"transport object","audience":"software"},"markdown":{"route":"/api/articles/tirzepatide-post-surgery/bundle?format=markdown","role":"portable explanation","audience":"human or model"},"directory":[]},"ontology":{"conformance_group":"article","inferred_from":["peptide","matrix","tirzepatide","post","surgery"],"relationships":[],"sources":[]},"conformance":{"success_events":"/api/articles/tirzepatide-post-surgery/invocations?status=success","failure_events":"/api/articles/tirzepatide-post-surgery/invocations?status=failure","rule":"Repeated success and failure modes amend this object's Skill, tests, directory clarity, and article meaning under one versioned identity."},"article":{"slug":"tirzepatide-post-surgery","title":"Tirzepatide After Surgery: Evidence on Weight Loss, Load Reduction, and Recovery Pathways","body":"## What's breaking down\n\nAfter any surgery, the body shifts into repair mode. Surgical trauma triggers inflammation, tissue remodeling, and healing cascades. Excess body weight adds mechanical stress that can slow this process. For spine or joint procedures, each extra pound transmits roughly four pounds of compressive force through lumbar discs and weight-bearing joints. If body weight remains high, repair can lag behind ongoing load, prolonging discomfort or increasing risk of complications like poor fusion or joint strain. Metabolic factors tied to obesity, such as chronic low-grade inflammation, may further tilt the balance toward slower recovery rather than regeneration.\n\n## Why Tirzepatide might help you\n\n1. What keeps failing: Post-surgical healing faces the same mechanical overload seen in other high-body-weight scenarios. Excess mass continues to stress healing tissues, incisions, or implanted hardware.\n\n2. What Tirzepatide is studied to do: It activates GLP-1 and GIP receptors, studied primarily for substantial weight reduction in adults with obesity. Human data show average losses of 15–20% body weight over 6–12 months in various populations.\n\n3. Therefore for you: If elevated body weight forms part of your post-operative challenge, Tirzepatide is discussed because it targets the metabolic-load layer through weight reduction. This may ease compressive forces on surgical sites and joints, supporting the body's natural repair processes rather than suppressing symptoms.\n\n## How these fit together\n\nThis is a single-compound focus. Tirzepatide addresses the metabolic-load and body-weight layer. In post-surgical contexts where weight regain or persistent obesity occurs, it aligns with repair by lowering mechanical demands on healing structures.\n\n## What the evidence actually shows\n\nHuman data come from retrospective cohort studies and ongoing trials focused on bariatric surgery patients. One 2024 retrospective study of 115 sleeve-gastrectomy patients with weight recurrence found tirzepatide produced 15.5% total weight loss at six months (human, source s7). Another observational cohort of 34 patients with recurrent weight gain after bariatric or endoscopic procedures reported 18.1% total body weight loss at 24 weeks (human, source s9). A 2025 analysis showed 14% of bariatric patients started GLP-1 drugs including tirzepatide post-surgery for weight management (human, source s5). Preoperative trials examine inflammation markers and outcomes but remain early-stage (human trials listed on clinicaltrials.gov, sources s1, s3, s8). No large randomized controlled trials specifically test tirzepatide for general post-surgical recovery or non-bariatric procedures.\n\nPreclinical data are absent from the reviewed sources for direct post-surgical models.\n\nAnecdotal reports on forums describe patients stopping the medication before procedures due to delayed gastric emptying concerns and resuming afterward for weight control.\n\n## What scientists say\n\nResearchers note robust weight loss in post-bariatric weight-recurrence settings and call for tailored use based on individual metabolic response. They emphasize that benefits appear tied to sustained weight reduction rather than direct tissue repair effects. Ongoing pilots like GRABS aim to quantify outcomes in persistent obesity one year after surgery.\n\n## What people say on Reddit\n\nUsers report being instructed to pause tirzepatide 1–6 weeks before surgery to reduce aspiration risk from slowed digestion. Some resume 4–6 weeks post-operatively for weight maintenance. Discussions in knee-replacement and tummy-tuck communities focus on timing around procedures rather than direct healing benefits.\n\n## What people say on X\n\nPosts mention tirzepatide use after weight-loss surgeries or in combination with other interventions. Perioperative management threads highlight skipping doses pre-op. One post references its approval for sleep apnea alongside obesity, noting indirect benefits for related surgical candidates.\n\n## What we do not know\n\nLong-term effects on bone healing, wound closure rates, or revision surgery needs remain unstudied in large human cohorts. Direct anti-inflammatory or anabolic actions independent of weight loss lack confirmation in post-surgical populations. Optimal timing relative to different procedure types is not standardized.\n\n## Safety and limits\n\nCommon effects include gastrointestinal symptoms such as nausea and constipation. Perioperative use requires coordination with surgical teams due to gastric-emptying changes. Weight-loss magnitude varies; not all patients achieve clinically meaningful reductions. Evidence for post-surgical applications beyond bariatric weight regain rests on smaller observational datasets rather than definitive trials.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/tirzepatide-post-surgery/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"Tirzepatide produced 15.5% total weight loss at six months in sleeve-gastrectomy patients with weight recurrence.","section":"What the evidence actually shows","tier":"human","source_ids":["s7"],"source_status":"sourced","why_material":"Demonstrates human outcome data specific to post-bariatric context.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:42:01.554Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"An observational cohort reported 18.1% total body weight loss at 24 weeks with tirzepatide after bariatric procedures.","section":"What the evidence actually shows","tier":"human","source_ids":["s9"],"source_status":"sourced","why_material":"Provides additional human cohort evidence for post-surgical weight management.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:42:01.554Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"14% of bariatric surgery patients initiated GLP-1 drugs including tirzepatide in follow-up up to 10 years post-op.","section":"What the evidence actually shows","tier":"human","source_ids":["s5"],"source_status":"sourced","why_material":"Shows real-world adoption rate after surgery.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:42:01.554Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Each extra pound of body weight transmits roughly four pounds of compressive force through lumbar discs.","section":"What's breaking down","tier":"mechanistic","source_ids":[],"source_status":"unsourced","why_material":"Explains load-reduction rationale for this reader.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:42:01.554Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s7","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/38430320/","title":"Semaglutide and Tirzepatide for the Management of Weight Recurrence After Sleeve Gastrectomy","quote":"mean post-treatment weight at 6 months ... 15.5 (6.3)% (p < 0.05)","summary":"Retrospective cohort of 115 SG patients; tirzepatide arm showed 15.5% weight loss at 6 months.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:41:59.711Z","link_status":"ok","quote_status":"unverified","prev":"genesis","hash":"f90611de14b38c876ac01a6dab20b0751b9fb5a47f4eaf9620ec8ac5cc27c1fa"},{"id":"s9","type":"pubmed","url":"https://link.springer.com/article/10.1007/s11695-026-08754-7","title":"Tirzepatide for Recurrent Weight Gain after Bariatric Procedures","quote":"mean percentage total body weight loss (%TBWL) was 18.1 ± 5.6% (p < 0.0001)","summary":"Observational cohort of 34 patients post-BS or EBT; 18.1% TBWL at 24 weeks.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:41:59.711Z","link_status":"ok","quote_status":"verified","prev":"f90611de14b38c876ac01a6dab20b0751b9fb5a47f4eaf9620ec8ac5cc27c1fa","hash":"28dcbe9b9125dc5140b2c9f83ef26f8837a96349870bd6af294c396831904312"},{"id":"s5","type":"news","url":"https://publichealth.jhu.edu/2025/one-in-seven-bariatric-surgery-patients-turn-to-new-weight-loss-drugs","title":"One in Seven Bariatric Surgery Patients Turn to New Weight Loss Drugs","quote":"a total of 15,749 patients (14%) began using GLP-1s","summary":"Johns Hopkins analysis of post-bariatric GLP-1 initiation rates.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T22:41:59.711Z","link_status":"http_403","quote_status":"unverified","prev":"28dcbe9b9125dc5140b2c9f83ef26f8837a96349870bd6af294c396831904312","hash":"ddacdfcca5e4f0c6bba778a5eded696bd219d139ebb6e58f3affc39eaa1bfd7d"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T22:42:02.016Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"Tirzepatide After Surgery: Evidence on Weight Loss, Load Reduction, and Recovery Pathways","register":"source_ledger","body":"## What's breaking down\n\nAfter any surgery, the body shifts into repair mode. Surgical trauma triggers inflammation, tissue remodeling, and healing cascades. Excess body weight adds mechanical stress that can slow this process. For spine or joint procedures, each extra pound transmits roughly four pounds of compressive force through lumbar discs and weight-bearing joints. If body weight remains high, repair can lag behind ongoing load, prolonging discomfort or increasing risk of complications like poor fusion or joint strain. Metabolic factors tied to obesity, such as chronic low-grade inflammation, may further tilt the balance toward slower recovery rather than regeneration.\n\n## Why Tirzepatide might help you\n\n1. What keeps failing: Post-surgical healing faces the same mechanical overload seen in other high-body-weight scenarios. Excess mass continues to stress healing tissues, incisions, or implanted hardware.\n\n2. What Tirzepatide is studied to do: It activates GLP-1 and GIP receptors, studied primarily for substantial weight reduction in adults with obesity. Human data show average losses of 15–20% body weight over 6–12 months in various populations.\n\n3. Therefore for you: If elevated body weight forms part of your post-operative challenge, Tirzepatide is discussed because it targets the metabolic-load layer through weight reduction. This may ease compressive forces on surgical sites and joints, supporting the body's natural repair processes rather than suppressing symptoms.\n\n## How these fit together\n\nThis is a single-compound focus. Tirzepatide addresses the metabolic-load and body-weight layer. In post-surgical contexts where weight regain or persistent obesity occurs, it aligns with repair by lowering mechanical demands on healing structures.\n\n## What the evidence actually shows\n\nHuman data come from retrospective cohort studies and ongoing trials focused on bariatric surgery patients. One 2024 retrospective study of 115 sleeve-gastrectomy patients with weight recurrence found tirzepatide produced 15.5% total weight loss at six months (human, source s7). Another observational cohort of 34 patients with recurrent weight gain after bariatric or endoscopic procedures reported 18.1% total body weight loss at 24 weeks (human, source s9). A 2025 analysis showed 14% of bariatric patients started GLP-1 drugs including tirzepatide post-surgery for weight management (human, source s5). Preoperative trials examine inflammation markers and outcomes but remain early-stage (human trials listed on clinicaltrials.gov, sources s1, s3, s8). No large randomized controlled trials specifically test tirzepatide for general post-surgical recovery or non-bariatric procedures.\n\nPreclinical data are absent from the reviewed sources for direct post-surgical models.\n\nAnecdotal reports on forums describe patients stopping the medication before procedures due to delayed gastric emptying concerns and resuming afterward for weight control.\n\n## What scientists say\n\nResearchers note robust weight loss in post-bariatric weight-recurrence settings and call for tailored use based on individual metabolic response. They emphasize that benefits appear tied to sustained weight reduction rather than direct tissue repair effects. Ongoing pilots like GRABS aim to quantify outcomes in persistent obesity one year after surgery.\n\n## What people say on Reddit\n\nUsers report being instructed to pause tirzepatide 1–6 weeks before surgery to reduce aspiration risk from slowed digestion. Some resume 4–6 weeks post-operatively for weight maintenance. Discussions in knee-replacement and tummy-tuck communities focus on timing around procedures rather than direct healing benefits.\n\n## What people say on X\n\nPosts mention tirzepatide use after weight-loss surgeries or in combination with other interventions. Perioperative management threads highlight skipping doses pre-op. One post references its approval for sleep apnea alongside obesity, noting indirect benefits for related surgical candidates.\n\n## What we do not know\n\nLong-term effects on bone healing, wound closure rates, or revision surgery needs remain unstudied in large human cohorts. Direct anti-inflammatory or anabolic actions independent of weight loss lack confirmation in post-surgical populations. Optimal timing relative to different procedure types is not standardized.\n\n## Safety and limits\n\nCommon effects include gastrointestinal symptoms such as nausea and constipation. Perioperative use requires coordination with surgical teams due to gastric-emptying changes. Weight-loss magnitude varies; not all patients achieve clinically meaningful reductions. Evidence for post-surgical applications beyond bariatric weight regain rests on smaller observational datasets rather than definitive trials.","claims":[{"id":"c1","text":"Tirzepatide produced 15.5% total weight loss at six months in sleeve-gastrectomy patients with weight recurrence.","section":"What the evidence actually shows","tier":"human","source_ids":["s7"],"source_status":"sourced","why_material":"Demonstrates human outcome data specific to post-bariatric context.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:42:01.554Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"An observational cohort reported 18.1% total body weight loss at 24 weeks with tirzepatide after bariatric procedures.","section":"What the evidence actually shows","tier":"human","source_ids":["s9"],"source_status":"sourced","why_material":"Provides additional human cohort evidence for post-surgical weight management.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:42:01.554Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"14% of bariatric surgery patients initiated GLP-1 drugs including tirzepatide in follow-up up to 10 years post-op.","section":"What the evidence actually shows","tier":"human","source_ids":["s5"],"source_status":"sourced","why_material":"Shows real-world adoption rate after surgery.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:42:01.554Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Each extra pound of body weight transmits roughly four pounds of compressive force through lumbar discs.","section":"What's breaking down","tier":"mechanistic","source_ids":[],"source_status":"unsourced","why_material":"Explains load-reduction rationale for this reader.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:42:01.554Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s7","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/38430320/","title":"Semaglutide and Tirzepatide for the Management of Weight Recurrence After Sleeve Gastrectomy","quote":"mean post-treatment weight at 6 months ... 15.5 (6.3)% (p < 0.05)","link_status":"ok","quote_status":"unverified"},{"id":"s9","type":"pubmed","url":"https://link.springer.com/article/10.1007/s11695-026-08754-7","title":"Tirzepatide for Recurrent Weight Gain after Bariatric Procedures","quote":"mean percentage total body weight loss (%TBWL) was 18.1 ± 5.6% (p < 0.0001)","link_status":"ok","quote_status":"verified"},{"id":"s5","type":"news","url":"https://publichealth.jhu.edu/2025/one-in-seven-bariatric-surgery-patients-turn-to-new-weight-loss-drugs","title":"One in Seven Bariatric Surgery Patients Turn to New Weight Loss Drugs","quote":"a total of 15,749 patients (14%) began using GLP-1s","link_status":"http_403","quote_status":"unverified"}]},"rationale":"","tokens_in":33100,"tokens_out":3014,"cost":0.04891,"prev_hash":"genesis","hash":"4480c510913ec67466eba0e5392b2db3f8bb489aa2ebee68e1238f12e9ac8d61"}],"provenance":[{"ts":"2026-06-29T22:42:02.016Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Tirzepatide for Post Surgery\nSlug: tirzepatide-post-surgery\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"tirzepatide\",\"name\":\"Tirzepatide\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"tirzepatide\",\"name\":\"Tirzepatide\",\"section_title\":\"Why Tirzepatide might help you\",\"layer\":\"metabolic load / body weight\",\"steps\":[\"**What keeps failing:** Same mechanical overload pattern as other GLP-1 contexts at higher body weight.\",\"**What Tirzepatide is studied to do:** Studied for GLP-1/GIP weight loss — load reduction on spine and joints.\",\"**Therefore for you:** If that layer is part of your problem, Tirzepatide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\"],\"prose\":\"1. **What keeps failing:** Same mechanical overload pattern as other GLP-1 contexts at higher body weight.\\n2. **What Tirzepatide is studied to do:** Studied for GLP-1/GIP weight loss — load reduction on spine and joints.\\n3. **Therefore for you:** If that layer is part of your problem, Tirzepatide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condit","response":"{\n  \"slug\": \"tirzepatide-post-surgery\",\n  \"title\": \"Tirzepatide After Surgery: Evidence on Weight Loss, Load Reduction, and Recovery Pathways\",\n  \"body\": \"## What's breaking down\\n\\nAfter any surgery, the body shifts into repair mode. Surgical trauma triggers inflammation, tissue remodeling, and healing cascades. Excess body weight adds mechanical stress that can slow this process. For spine or joint procedures, each extra pound transmits roughly four pounds of compressive force through lumbar discs and weight-bearing joints. If body weight remains high, repair can lag behind ongoing load, prolonging discomfort or increasing risk of complications like poor fusion or joint strain. Metabolic factors tied to obesity, such as chronic low-grade inflammation, may further tilt the balance toward slower recovery rather than regeneration.\\n\\n## Why Tirzepatide might help you\\n\\n1. What keeps failing: Post-surgical healing faces the same mechanical overload seen in other high-body-weight scenarios. Excess mass continues to stress healing tissues, incisions, or implanted hardware.\\n\\n2. What Tirzepatide is studied to do: It activates GLP-1 and GIP receptors, studied primarily for substantial weight reduction in adults with obesity. Human data show average losses of 15–20% body weight over 6–12 months in various populations.\\n\\n3. Therefore for you: If elevated body weight forms part of your post-operative challenge, Tirzepatide is discussed because it targets the metabolic-load layer through weight reduction. This may ease compressive forces on surgical sites and joints, supporting the body's natural repair processes rather than suppressing symptoms.\\n\\n## How these fit together\\n\\nThis is a single-compound focus. Tirzepatide addresses the metabolic-load and body-weight layer. In post-surgical contexts where weight regain or persistent obesity occurs, it aligns with repair by lowering mechanical demands on healing structures.\\n\\n## What the evidence actually shows\\n\\nHuman dat","tokens_in":33100,"tokens_out":3014,"cost":0,"prev":"genesis","hash":"7068a11d771160d8dc08950dc802531fc6cd78cbcf4f1ed2ad8dd495fd3562ca"},{"ts":"2026-07-17T02:43:18.784Z","model":"owner","action":"voxel_divide","prompt":"","input":"tirzepatide-post-surgery","response":"22 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"7068a11d771160d8dc08950dc802531fc6cd78cbcf4f1ed2ad8dd495fd3562ca","hash":"a3ffd50c81b6bf2c4483a20dab52dd3be1fc7b1cedd3f62d3d9a928f18096740"}],"energy":{"passes":2,"tokens_in":33100,"tokens_out":3014,"tokens_total":36114,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"a3ffd50c81b6bf2c4483a20dab52dd3be1fc7b1cedd3f62d3d9a928f18096740"},"posted_at":"2026-06-29T21:33:46.498Z","created_at":"2026-06-29T21:33:46.498Z","updated_at":"2026-07-17T02:43:18.784Z","machine":{"shape":"article.machine/v1","slug":"tirzepatide-post-surgery","kind":"article","read":{"human":"https://miscsubjects.com/a/tirzepatide-post-surgery","json":"https://miscsubjects.com/api/articles/tirzepatide-post-surgery","bundle":"https://miscsubjects.com/api/articles/tirzepatide-post-surgery/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":4,"sources":3,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/tirzepatide-post-surgery/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=tirzepatide-post-surgery","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"tirzepatide-post-surgery\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"tirzepatide-post-surgery\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/tirzepatide-post-surgery/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"tirzepatide-post-surgery\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/tirzepatide-post-surgery | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/tirzepatide-post-surgery","json":"/api/articles/tirzepatide-post-surgery","markdown":"/api/articles/tirzepatide-post-surgery/bundle?format=markdown","skill":"/api/articles/tirzepatide-post-surgery/skill","topology":"/api/articles/tirzepatide-post-surgery/topology","versions":"/api/articles/tirzepatide-post-surgery/revisions","invocations":"/api/articles/tirzepatide-post-surgery/invocations"},"editorial_review":null,"editorial_audit":{"slug":"tirzepatide-post-surgery","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"6d63f032880949207ad5cff6f07d8464b615c12ea17b6e8bca304c7eeea6a96f"}}}